Reig Jofre starts marketing of three new injectble products for hospitals

Developments correspond to generic products based on specialized pharmaceutical technologies.

Bivalirrudine 250 mg (active ingredient, Bivalirrudin) is a lyophilized injectable anticoagulant, indicated in both adult patients who undergo a percutaneous coronary intervention, including patients with myocardial infarction, and in the treatment of adult patients with unstable angina who will be subjected to an urgent or early surgery.

Bivalirrudine has been co-developed by the R&D team of the Barcelona injectable plant in collaboration with AMBIOPHARM, the North American developer and manufacturer of the active ingredient. The product is being registered in 16 markets (US among them) and is already being marketed in Spain, Denmark, Sweden, the UK and Australia. In the coming months, it is expected to start marketing this injectable in other countries.

Palonosetron 5 mg (active ingredient, Palonosetron HCl) is an injectable antiemetic indicated for the prevention of acute nausea and vomiting associated with cancer chemotherapy in adults, adolescents and children over one month old.

Also, developed in the Barcelona injectable plant, Palonestron has been registered in six markets and is already being marketed in Spain, UK, Denmark and Sweden.

Cefepime 1 g (active ingredient, Cefepime-Arginine) is an injectable antibiotic belonging to cephalosporin group, indicated in the treatment of respiratory, urinary and gastric infections, among others, caused by bacteria. This injectable, developed by the R&D team of the Toledo penicillin plant, has been registered in Spain, where it is already marketed.

To market its developments, Reig Jofre has its own sales network in six European markets, and business relationships with 130 partners in 63 countries on five continents. The company confirms its firm commitment to internationalization, whose spearhead is the line of antibiotics and injectable products for hospitals, the latter strongly boosted in 2016 by the entry in Japan.